Who stands to benefit from - or lose out on - gene editing? Advances in our ability to tweak the human genome using CRISPR Cas-9 and similar techniques won’t only affect those at risk of genetic disorders. Women and disabled people are likely to be disproportionately affected. And people living in poor countries - who are at the greatest risk of disease - could miss out on the benefits. These were among the points raised at a summit held by the US National Academies of Science and Medicine’s Committee on Human Gene Editing in Paris today. The committee will draw up a set of recommendations based on the questions and comments raised by the audience - a mix of scientists, ethicists and lawyers.